Leaky Gut Supplements: What the Human Evidence Actually Supports

Your gut lining is not a sealed pipe, and it is not supposed to leak. It sits somewhere in between, and that balance is what this article is about. Below you will find what intestinal permeability actually is, which leaky gut supplements have real human trials behind them, the doses those trials used, and what the research does not support. Several popular recommendations have no human barrier evidence at all, and the most widely sold test for the problem does not measure what it claims to. Knowing that will save you money. The barrier is real, it can be measured, and a small number of well-studied nutrients and habits are worth your attention.

What "Leaky Gut" Actually Means

Your gut lining is a single layer of cells, one cell thick, doing two opposite jobs at once. It lets nutrients through and keeps almost everything else out. When that balance slips, larger molecules cross into the bloodstream than should, and the body reacts.

The cells are sealed to one another by tight junctions, protein complexes that act like adjustable seams. Between those seams runs the paracellular route, the path that goes between cells rather than through them. When the seams loosen, more traffic moves along it. That is what people mean by intestinal permeability, or "leaky gut."

Three parts do the work:

• The mucus layer. A gel of proteins that sits on top of the cells and keeps most bacteria at a distance.
• The epithelial cells. The single sheet itself, each cell joined to its neighbours by tight junctions.
• The immune tissue beneath. A dense layer of immune cells that samples what gets through and decides how to respond.

All three work together, so the barrier is a system rather than a wall. Quigley makes that point directly: permeability testing captures only one of the barrier's functions, the passage of molecules between cells (Quigley 2016).

The words themselves are loose too. A review in BMC Gastroenterology found that "intestinal barrier" and "intestinal permeability" are poorly defined, that their assessment is a matter of debate, and that their clinical significance is not clearly established (Bischoff 2014). That is a reason to be precise, not to dismiss the topic. Picture permeability as a dial with a normal range rather than a switch that is either on or off.

Is Leaky Gut Real? What Is Measurable and What Is Not

The short answer is two sentences long. The barrier is real and it can be measured. "Leaky gut syndrome" is not a diagnosis you can be given.

What is genuinely measurable. Researchers measure how much of a sugar probe crosses the gut lining. In the lactulose/mannitol ratio test, a person drinks both sugars; a healthy gut absorbs mannitol easily and lets very little lactulose through, so more lactulose in the urine means more paracellular leak. In two cohorts, one of 51 healthy adults and one of 27 people with obesity, that ratio tracked with plasma LBP, a marker of bacterial exposure (Seethaler 2021). The lactulose/rhamnose ratio works the same way, and in 34 healthy adults it correlated with LPS (r = 0.536, P = 0.018) (Tatucu-Babet 2020). The sucralose to lactulose ratio looks at the colon instead of the small intestine (Krumbeck 2018), and collection windows change the numbers, which is why one crossover study focused purely on the method (Camilleri 2010). In the lab, transepithelial electrical resistance, or TER, measures a sheet of gut cells in a dish: good for mechanism, useless for telling you about your own body.

Even the best of these is a research tool rather than a clinical one. A systematic review of 25 lactulose/mannitol studies in children called the test useful but said better technical performance, better data reporting, and better correlation with what actually happens to people are all still needed (Denno 2014). That review covered children in developing-country settings, so it speaks to environmental gut damage rather than adult "leaky gut" in general.

The zonulin problem. Zonulin is sold as the blood marker for leaky gut, and that description does not hold up. A 2019 study using immunoprecipitation, mass spectrometry, and gel analysis found the antigens detected by two widely used commercial zonulin ELISA kits, from CUSABIO and Immundiagnostik, were haptoglobin and complement C3, not zonulin (Ajamian 2019). Serum zonulin also showed no relationship to the lactulose/rhamnose ratio in healthy adults (r = -0.016, P = 0.929) (Tatucu-Babet 2020), and in liver cirrhosis a 2025 meta-analysis concluded zonulin cannot be considered a permeability marker at all (Dumitru 2025). When you see a zonulin number quoted, the honest version of that sentence includes what the kit is actually measuring.

What is not established. No source in this evidence set establishes "leaky gut syndrome" as a clinical entity (Quigley 2016). More importantly, fixing the barrier is not the same as fixing a disease. Camilleri, writing in Gut, is explicit: while inflammatory and ulcerating intestinal diseases do produce leaky gut, "no such disease can be cured by simply normalizing intestinal barrier function," and "it is still unproven that restoring barrier function can ameliorate clinical manifestations in GI or systemic diseases" (Camilleri 2019). Quigley reaches the same place: "at present, few studies support efficacy for an intervention that improves barrier function in altering the natural history of a disease process" (Quigley 2016).

That does not make barrier support pointless. It defines the honest target. You can support a barrier. You cannot treat a diagnosis by repairing one.

The association story is weaker than it is usually told. Bischoff and colleagues list conditions linked to permeability, including critical illness, inflammatory bowel disease, coeliac disease, IBS, and obesity and metabolic disease, all marked by inflammation that "might be triggered" by material crossing the lining (Bischoff 2014). Associated with, mechanism unproven. One study found permeability higher in fatty liver disease and correlated with liver fat but not with more advanced disease (Miele 2009), while another found permeability and endotoxin similar in patients and controls (Wigg 2001). A small study in early Parkinson's disease found greater permeability alongside markers of bacterial exposure (Forsyth 2011). None of these can show which came first.

What Increases Intestinal Permeability

Permeability is not fixed. It moves with what you take in, what your body is fighting, and how much stress it is under.

NSAIDs. Among the clearest human signals. In a randomized crossover trial in 10 healthy volunteers, indomethacin produced a threefold rise in gut permeability, with the lactulose/rhamnose ratio climbing from 0.35 to 0.88 (p<0.01) (Mahmood 2007).

Strenuous exercise and heat. A standardized run raised permeability threefold, from 0.32 to 1.0 (P<0.01), in eight athletes (Davison 2016), and a separate study of eight exercisers found permeability higher after a 60-minute treadmill run in the placebo condition than at baseline (Zuhl 2014). Both used small groups of already-fit people under heat and exertion stress.

Gut infection. The glutamine trial below recruited people whose permeability was still raised after an enteric infection (Zhou 2019). Post-infection permeability is one of the better documented routes, and our guide to rebuilding the gut after antibiotics covers the recovery side.

Dietary patterns. The strongest evidence here is not in humans. A mouse study found a four-week high-fat diet raised plasma LPS two- to threefold, the finding usually called metabolic endotoxemia (Cani 2007). It is a rodent result widely cited as though it settled the human question.

Dysbiosis and small intestinal bacterial overgrowth. Bacterial overgrowth was more common in the patient group in the fatty liver study above (Wigg 2001), and a second study found higher overgrowth prevalence alongside higher permeability (Miele 2009). Our guide to SIBO versus leaky gut explains how the two overlap and how they differ.

Alcohol and psychological stress. Both are commonly named as permeability triggers. In the verified evidence set behind this article, the human data are strongest for NSAIDs, strenuous exercise, and gut infection, so treat the alcohol and stress links as plausible rather than directly measured here.

The Supplements, Ranked by Evidence

Most supplement lists mix everything together. This one separates two questions. Has a human trial measured a barrier or permeability endpoint for this nutrient? And if not, what is the evidence actually based on? A cell study and a randomized trial are not the same kind of evidence, and the gap between them is where most leaky gut marketing lives. Tier one is short. Tier two is long, and it includes nutrients you have probably been told to take.

What Human Trials Have Actually Tested

Glutamine has the strongest single human permeability signal, and one of the most important nulls. In a trial in people with diarrhea-predominant IBS whose permeability was still raised after a gut infection, the primary symptom endpoint was met in 43 of 54 completers (79.6%) against 3 of 52 (5.8%) on placebo, and, as a secondary endpoint, permeability fell from 0.11 to 0.05 (p<0.0001) (Zhou 2019). The authors called for large trials to validate those numbers. The null came elsewhere: in 84 critically ill patients, a glutamine-enriched enteral diet did not change permeability on the lactulose/mannitol test in either group (Conejero 2002). Glutamine may help in one context and do nothing measurable in another.

Zinc carnosine is the other nutrient with a direct human permeability result. Indomethacin raised permeability threefold on its own, but no significant rise occurred when zinc carnosine was given alongside it (Mahmood 2007), and a second trial found 14 days of it cut an exercise-induced rise by about 70% (Davison 2016). Plain zinc is a separate story: in children with diarrhea, zinc reduced lactulose excretion but the lactulose/mannitol ratio did not differ between groups (Roy 1992). One probe moved and the ratio did not.

Vitamin D has one relevant trial, and it is small. In 27 Crohn's patients in remission, 2000 IU per day for three months held permeability steady in the treated group while it rose from baseline on placebo (Raftery 2015). That is a within-group comparison, so the fair reading is that permeability did not worsen. A separate 12-week trial of 35 people with IBS lowered zonulin with a multistrain probiotic plus vitamin D, but the lactulose/mannitol ratio and symptom scores did not differ (Laterza 2025).

Probiotics and prebiotics get their own section below, because the results are strain-specific in a way a table cannot carry.

What Is Preclinical Only

Everything here has real science behind it. None of it includes a human trial with a barrier endpoint.

Butyrate is a good mechanism never tested in people for this purpose. In Caco-2 cell monolayers it strengthens tight junctions by activating AMPK (Peng 2009), and the effect flips with dose: 2 mM increased transepithelial resistance and lowered permeability, while 8 mM reduced resistance and increased permeability (Peng 2007). More is not better here. It may be worse. The only human oral butyrate trial found 4 grams a day for four weeks did not raise plasma or fecal butyrate at all (Bouter 2018).

Omega-3 has one human study, and its authors labeled it exploratory. In 68 women on a Mediterranean or standard diet, higher plasma DHA tracked with better barrier markers, but the effect was smaller than that of fecal short-chain fatty acids, and the control group improved too (Seethaler 2023). A targeted search for human randomized trials of omega-3 with permeability as an outcome returned nothing.

Collagen, gelatin, and collagen peptides have no human gut barrier evidence at all. This is a gap in the literature, not in our reading. What exists is either about collagen peptides being absorbed through the gut rather than improving it (Sontakke 2016), or about gelatin tannate, an astringent drug-like compound, in mice with colitis, which is not dietary gelatin (Scaldaferri 2014).

Saccharomyces boulardii has a solid human evidence base for antibiotic-associated diarrhea, including a meta-analysis of 31 randomized placebo-controlled arms covering 5,029 patients (McFarland 2010). That meta-analysis had no permeability outcome. Its barrier evidence is animal and laboratory work, as it is for glycine and arginine, where the retrieved barrier studies were in broiler chickens and piglets.

The Doses Human Trials Actually Used

Doses are where most articles go quiet, so here they are, each with the group it came from and the caveat that belongs with it.

Glutamine: 5 grams three times daily, 15 grams per day, for 8 weeks. Cohort: 54 glutamine and 52 placebo completers with diarrhea-predominant IBS and raised permeability after an enteric infection (Zhou 2019). Caveats: a narrow subgroup, an unusually large effect size for a nutrient, and the authors' own call for large trials. A second trial added 15 grams per day to a low-FODMAP diet for 6 weeks and reported more than 45% symptom improvement in 22 of 25 people (88%) against 15 of 25 (60%, p=0.015), but permeability was not measured and only 22 people per group completed (Rastgoo 2021). Our guide to what the glutamine trials actually used goes deeper. If you go looking for it, a plain L-glutamine powder is the form and the order of magnitude those trials used.

Zinc carnosine: 37.5 milligrams twice daily, 75 milligrams per day. Cohort: 10 healthy volunteers, with permeability challenged by indomethacin rather than by disease (Mahmood 2007). Caveat: small, healthy, and challenge-induced. A second study used 14 days in 8 athletes before a standardized exercise test (Davison 2016). This is zinc carnosine specifically. Plain zinc at 5 mg/kg/day in children gave a mixed result (Roy 1992). If you want the form both of those trials actually used, that is a zinc carnosine capsule and not a plain zinc tablet.

Vitamin D: 2000 IU per day for 3 months. Cohort: 27 Crohn's patients in remission, a small disease cohort rather than a general population (Raftery 2015). Caveat: a within-group comparison, so the honest reading is that permeability did not worsen.

Probiotics: the strain and the duration are the dose. A single "probiotic" number tells you very little.

• Lactobacillus rhamnosus 19070-2 plus L. reuteri DSM 12246, 6 weeks. 41 children with atopic dermatitis; the lactulose/mannitol ratio was lower on the probiotic (0.073) than on placebo (0.110, P=.001) (Rosenfeldt 2004). Note the strains carefully. They are not L. rhamnosus GG.
• Bifidobacterium adolescentis IVS-1 and B. lactis BB-12, 3 weeks. Adults with obesity; the sucralose to lactulose ratio, measured after an aspirin challenge, fell on IVS-1 (P=0.050), on IVS-1 plus a galacto-oligosaccharide (P=0.022), and on the galacto-oligosaccharide alone (P=0.010), with no change in endotoxemia markers (Krumbeck 2018).
• Lactobacillus rhamnosus GG ATCC 53103, daily for 4 weeks. 124 children aged 6 months to 5 years with rotavirus or cryptosporidial diarrhea; those with cryptosporidial diarrhea improved significantly on intestinal permeability (Sindhu 2014). The lactulose/mannitol ratio was one of several outcomes, not the single pre-specified primary endpoint.
• A multistrain probiotic plus vitamin D, 12 weeks. 35 people with IBS; zonulin fell but the lactulose/mannitol ratio and symptom scores did not differ (Laterza 2025).

Every dose above comes from a specific group of people under specific conditions. None is a general recommendation, and none comes with a guarantee of the same result in a different body.

Probiotics: Why the Strain Matters

Probiotics are the most recommended and least precise item on every leaky gut list. The human permeability data are strain-specific. "Probiotic" is a category, not an ingredient.

A 2025 systematic review and meta-analysis pooled 46 probiotic and synbiotic studies and 22 prebiotic studies. Probiotics and synbiotics reduced LPS with a standardized mean difference of -0.54 (95% CI -1.01 to -0.07) across 24 trials and 1,603 participants, but with an I-squared of 94.4% and very low certainty of evidence. Zonulin fell by -0.49 (95% CI -0.79 to -0.18) across 13 trials and 778 participants at moderate certainty. Prebiotics reduced LPS by -0.88 (95% CI -1.28 to -0.47) across 16 randomized trials and 792 participants at high certainty (Ghorbani 2025). The largest probiotic effect is the one the authors are least confident in, and the most confident result in the paper belongs to prebiotic fiber.

An earlier meta-analysis of nine trials found probiotics and synbiotics lowered serum zonulin by 10.55 (95% CI -17.76 to -3.34, P=0.004) with very high heterogeneity (I-squared 97.8, P<0.001) (Ramezani Ahmadi 2020). That result depends on the contested zonulin assays described above.

The positive human trials are worth naming precisely.

• Bifidobacterium adolescentis IVS-1 and B. lactis BB-12 improved colonic permeability in adults with obesity over 3 weeks, without changing endotoxemia markers (Krumbeck 2018).
• L. rhamnosus 19070-2 with L. reuteri DSM 12246 lowered the lactulose/mannitol ratio in 41 children with atopic dermatitis over 6 weeks (Rosenfeldt 2004).
• L. rhamnosus GG ATCC 53103 improved intestinal permeability in children with cryptosporidial diarrhea over 4 weeks (Sindhu 2014).

A misattribution worth knowing. The pediatric atopic dermatitis trial is often cited as proof that L. rhamnosus GG repairs the gut barrier. It is not. That trial used L. rhamnosus 19070-2 and L. reuteri DSM 12246, two different strains (Rosenfeldt 2004). The human LGG permeability result comes from a different study, in children with a gut infection.

The nulls matter just as much.

• 200 overweight pregnant women taking B. animalis ssp. lactis 420 and L. rhamnosus HN001, with or without omega-3 fatty acids, showed no effect on either permeability marker (Mokkala 2018).
• Six months of a multistrain probiotic in people with fatty liver disease produced no positive change in small intestinal permeability (Ayob 2023).
• 90 intensive care patients given a synbiotic had fewer potentially pathogenic bacteria at one week but no difference in intestinal permeability, septic complications, or mortality (Jain 2004).

Three well-designed trials, three clean nulls. A good probiotic choice starts with knowing that. For how to pick a product, see our guide to how to choose a probiotic. If you have an active bacterial overgrowth picture, fiber strategies are the part most likely to need individual guidance.

Diet and Lifestyle: Where the Evidence Is Strongest

The most confident finding in this whole area is not a supplement. It is fiber. The same 2025 meta-analysis found prebiotics reduced LPS across 16 randomized trials and 792 participants at high certainty, the strongest grading it gave any intervention (Ghorbani 2025).

That fits the mechanism. Butyrate is made when gut bacteria ferment fiber, and a review of diet-modulated butyrate production found that production is readily adjustable by dietary fiber, while how much that changes barrier function and inflammatory markers is more variable (Bach Knudsen 2018). You can change the raw material fairly reliably. Nobody can yet promise you the downstream result. It is also why fiber, not fish oil, is the better bet: in the LIBRE trial analysis, the short-chain fatty acid effect on barrier markers was larger than the omega-3 effect (Seethaler 2023).

The practical directions that follow:

• Feed the bacteria that make butyrate. Fiber-rich foods and prebiotic fibers are the lever with the highest certainty of evidence here.
• Follow a Mediterranean-style pattern. The LIBRE trial found barrier markers improving on a Mediterranean diet compared with a standard diet (Seethaler 2023). It was exploratory and the control group improved too, so treat it as supportive rather than conclusive.
• Review your NSAID use with your doctor. The indomethacin signal is one of the clearest in this evidence set (Mahmood 2007).
• Be cautious with alcohol, protect sleep, and manage stress. All three are widely named as permeability factors, and this evidence set does not include a human permeability trial for any of them.
• Treat fermented foods as a reasonable addition. A sensible habit, but we did not find a human permeability trial for them here.

If you want to see what a gut-supportive catalog looks like in practice, browse the digestion and GI support collection. For how digestion, absorption, and the barrier fit together, start with our Digestion & Gut Health pillar.

What Does Not Work

This section exists because the other articles on this topic do not have one. These are claims we looked for and could not support.

Collagen and gelatin for the gut lining. There is no human study of any collagen or gelatin product with an intestinal permeability or barrier endpoint. Four separate database searches, with and without human filters, returned nothing. The studies cited instead are about something else: collagen peptides being absorbed through the gut, which is the opposite of repairing it (Sontakke 2016), and gelatin tannate, an astringent compound that is not dietary gelatin, in mice with colitis (Scaldaferri 2014).

Butyrate pills for the barrier. The mechanism is real and it has never been tested in humans with a barrier endpoint. The tight-junction data come from cell monolayers (Peng 2007, Peng 2009). The one human oral butyrate trial found 4 grams a day for four weeks did not raise plasma or fecal butyrate (Bouter 2018). In cells, the protective effect at 2 mM reversed into a disruptive effect at 8 mM (Peng 2007). We are not going to give you a butyrate dose, because there is no human permeability trial to draw one from.

Omega-3 as a barrier intervention. One human study surfaced. It was explicitly exploratory, open-label, and uncontrolled, and its own comparison found the control group improving as well (Seethaler 2023). A targeted search for randomized human trials of omega-3 with permeability as an outcome returned zero records.

Saccharomyces boulardii for permeability. Its human evidence is for antibiotic-associated diarrhea, with a strong meta-analysis behind it (McFarland 2010). That meta-analysis had no permeability outcome, and its barrier evidence is animal and laboratory work.

At-home zonulin panels. Two common commercial kits detect haptoglobin and complement C3 rather than zonulin (Ajamian 2019), serum zonulin did not correlate with the lactulose/rhamnose ratio in healthy adults (Tatucu-Babet 2020), and zonulin is unusable as a permeability marker in cirrhosis (Dumitru 2025).

Heal your gut in two weeks. No trial in this evidence set set out to repair an already-damaged barrier over a two-week window. The shortest positive results were 14 days of pre-supplementation in healthy athletes before an exercise challenge (Davison 2016) and 3 weeks in adults with obesity (Krumbeck 2018).

Metabolic endotoxemia as an established human fact. The foundational citation is a mouse study (Cani 2007), and there is a direct human null in the same area (Wigg 2001).

"Leaky gut syndrome" as a diagnosable condition. No source retrieved for this article establishes it as a clinical entity (Quigley 2016). The barrier is a research concept with real measurements attached. It is not a diagnosis.

Should You Test for Leaky Gut?

The real tests exist, and they are research tools. The lactulose/mannitol and lactulose/rhamnose ratio tests measure how much of two sugar probes crosses your gut lining. The sucralose to lactulose ratio looks at the colon. Transepithelial electrical resistance measures a sheet of cells in a laboratory.

Why they are research tools rather than clinical ones:

• Test performance still needs work. A systematic review of 25 lactulose/mannitol studies called for improved technical performance, better data reporting, and better correlation with what actually happens to people (Denno 2014).
• Results move with method. Collection windows alone change the numbers (Camilleri 2010).
• The surrogate markers validate against each other rather than defining a diagnosis, which supports their use in research rather than establishing a clinical test (Seethaler 2021).
• The popular blood marker is contested, for the reasons above (Ajamian 2019).

So our honest answer to "should I buy a home leaky gut panel" is usually no. A test reporting a zonulin number is likely reporting something other than zonulin, and even an accurate permeability result would not tell you which supplement to take (Camilleri 2019). What matters more is that the product you buy is what the label says it is, and you can read how Agape vets what it stocks for how that work is done.

How Long It Actually Takes

The trial durations are the only honest basis for an answer.

• 8 weeks for 15 grams a day of glutamine (Zhou 2019)
• 6 weeks for glutamine added to a low-FODMAP diet (Rastgoo 2021)
• 4 weeks for L. rhamnosus GG in children with a gut infection (Sindhu 2014)
• 3 weeks for Bifidobacterium strains and a galacto-oligosaccharide in adults with obesity (Krumbeck 2018)
• 12 weeks for a multistrain probiotic plus vitamin D (Laterza 2025)
• 3 months for vitamin D at 2000 IU per day (Raftery 2015)
• 14 days for zinc carnosine before an exercise challenge (Davison 2016)

So can you heal a leaky gut in two weeks? The shortest human result with a positive permeability signal was 14 days, and that was in healthy athletes under a controlled exercise challenge, supported by a nutrient taken before the challenge rather than after months of damage (Davison 2016). The shortest result in a metabolic-syndrome-type population was 3 weeks (Krumbeck 2018).

For the changes most people are actually trying to make, plan in weeks to months. The glutamine signal took 8 weeks and the vitamin D result took 3 months. If a program promises a two-week repair, it is not drawing that timeline from human barrier research. One more thing: these durations are about measured permeability, not about how you feel, and symptoms and barrier markers do not always move together (Laterza 2025).

When to Talk to a Healthcare Provider

Some situations deserve a clinician rather than a supplement aisle.

• Ongoing diarrhea, unintended weight loss, blood in your stool, or pain that wakes you at night.
• A diagnosed digestive condition, or any condition where your treatment plan depends on your gut.
• Any regular prescription medication routine, and especially regular NSAID use, since the permeability signal for NSAIDs is the clearest one in this article (Mahmood 2007).
• Pregnancy, breastfeeding, or care for a child. Several studies above were in children, and pediatric dosing is a clinical decision rather than a label decision.
• Before starting any new supplement if you take prescription medication, because interactions are specific and real.

A useful way to frame the conversation: the barrier is real and measurable, and normalizing it is not a proven way to change the course of a disease (Camilleri 2019, Quigley 2016). Ask what the evidence is for a specific intervention, not for the concept. Agape Nutrition has been selling practitioner-grade supplements since 1998, which shapes what the catalog carries, and it does not replace your own clinician.

What We Recommend

These are barrier-support products, matched to the evidence tiering above rather than to the size of the claim on the label. None of them cures anything, none of them is a treatment for a diagnosis, and none replaces the clinician conversation in the previous section. Each one lines up with a nutrient or a category that has a human trial behind it, which is a much shorter list than the shelf suggests. Prices are the current Agape price.

References

1. Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS One 14(1):e0210728, 2019.
2. Ayob N, et al. The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease. Biomedicines 11(2):640, 2023.
3. Bach Knudsen KE, et al. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients 10(10):1499, 2018.
4. Bischoff SC, et al. Intestinal permeability: a new target for disease prevention and therapy. BMC Gastroenterol 14:189, 2014.
5. Bouter K, et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. Clin Transl Gastroenterol 9(5):155, 2018.
6. Camilleri M, et al. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. Neurogastroenterol Motil 22(7), 2010.
7. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 68(8), 2019.
8. Cani PD, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7), 2007.
9. Conejero R, et al. Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome. Nutrition 18(9), 2002.
10. Davison G, et al. Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. Am J Clin Nutr 104(2), 2016.
11. Denno DM, et al. Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: a systematic review. Clin Infect Dis 59 Suppl 4:S213-9, 2014.
12. Dumitru A, et al. Intestinal permeability assessed by serum zonulin in liver cirrhosis: a systematic review and meta-analysis. Medicine (Baltimore) 104(15), 2025.
13. Forsyth CB, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6(12):e28032, 2011.
14. Ghorbani Z, et al. Reinforcing gut integrity: a systematic review and meta-analysis of clinical trials assessing probiotics, synbiotics, and prebiotics on intestinal permeability markers. Pharmacol Res 216:107780, 2025.
15. Jain PK, et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin Nutr 23(4), 2004.
16. Krumbeck JA, et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome 6(1):109, 2018.
17. Laterza L, et al. Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in IBS without constipation. Nutrients 17(10):1708, 2025.
18. Mahmood A, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut 56(2), 2007.
19. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16(18):2202-22, 2010.
20. Miele L, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6), 2009.
21. Mokkala K, et al. The impact of probiotics and n-3 long-chain polyunsaturated fatty acids on intestinal permeability in pregnancy: a randomised clinical trial. Benef Microbes 9(1), 2018.
22. Peng L, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61(1), 2007.
23. Peng L, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139(9), 2009.
24. Quigley EM. Leaky gut: concept or clinical entity? Curr Opin Gastroenterol 32(2), 2016.
25. Raftery T, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United European Gastroenterol J 3(3), 2015.
26. Ramezani Ahmadi A, et al. The effects of probiotic/synbiotic on serum level of zonulin as a biomarker of intestinal permeability: a systematic review and meta-analysis. Iran J Public Health 49(7), 2020.
27. Rastgoo S, et al. Glutamine supplementation enhances the effects of a low FODMAP diet in irritable bowel syndrome management. Front Nutr 8:746703, 2021.
28. Rosenfeldt V, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 145(5), 2004.
29. Roy SK, et al. Impact of zinc supplementation on intestinal permeability in Bangladeshi children with acute diarrhoea and persistent diarrhoea syndrome. J Pediatr Gastroenterol Nutr 15(3), 1992.
30. Scaldaferri F, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition. United European Gastroenterol J 2(2), 2014.
31. Seethaler B, et al. Biomarkers for assessment of intestinal permeability in clinical practice. Am J Physiol Gastrointest Liver Physiol 321(1), 2021.
32. Seethaler B, et al. Omega-3 polyunsaturated fatty acids improve intestinal barrier integrity, albeit to a lesser degree than short-chain fatty acids: an exploratory analysis of the randomized controlled LIBRE trial. Eur J Nutr 62(7), 2023.
33. Sindhu KN, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 58(8), 2014.
34. Sontakke SB, et al. Orally available collagen tripeptide: enzymatic stability, intestinal permeability, and absorption of Gly-Pro-Hyp and Pro-Hyp. J Agric Food Chem 64(38), 2016.
35. Tatucu-Babet OA, et al. Serum zonulin measured by ELISA may not be a reliable marker of small intestinal permeability in healthy adults. Nutr Res 78:49-59, 2020.
36. Wigg AJ, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48(2), 2001.
37. Zhou Q, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut 68(6), 2019.
38. Zuhl MN, et al. Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression. J Appl Physiol 116(6), 2014.

Frequently Asked Questions